CD274 and non-small cell lung carcinoma: Recently, immune checkpoint therapy, which was designed to inhibit programmed death-1 (PD-1) or the ligand PD-L1 to prevent T cell exhaustion and induce prolonged antitumor immunity, has revolutionized the treatment for advanced-stage NSCLC (4–6).